VivoSeq
Metabolic & Endocrine

Type 2 Diabetes Mellitus

590

Pipeline Programs↗

81

Active Trials↗

145

Companies Involved↗

Type 2 Diabetes Mellitus is a highly competitive landscape with 590 programs across 145 companies. The most active players are PhaseBio Pharmaceuticals Inc., Shionogi, Gilead. 144 therapies are approved with 139 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

96/100

Pipeline Velocity

69/100

Mech. Concentration

6/100

Completion Rate

88/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

PhaseBio Pharmaceuticals Inc.

2 programs

Phase 1Shionogi logo

Shionogi

2 programs

Phase 1Gilead logo

Gilead

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.

1 program

Phase 1F

Fujian Shengdi Pharmaceutical Co., Ltd.

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

95%

Small molecule

607 of 639 classified programs — the dominant modality here.

5%ALL OTHERSPeptide223%Cell therapy6<1%Protein / enzyme2<1%Monoclonal antibody1<1%Vaccine1<1%

Small molecule leads; the ring shows all 639 classified programs, each share of the total. Modality classified for 98% of 677 pipeline programs.

Analysis

Trial Status

1,022

clinical trials

Completed762 · 75%
Terminated82 · 8%
Unknown status76 · 7%
Recruiting34 · 3%
Not yet recruiting28 · 3%
Withdrawn21 · 2%
Other19 · 2%

Clinical Trials

Trial Activity

1022 trials

Safety and Efficacy of OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Refractory Type 2 Diabetes Mellitus
Recruiting·LLu jin ，MD·Phase 2·NCT06727721·10 enrolled
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
Recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 3·NCT07193459·360 enrolled
To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Recruiting·HHyundai Pharm·Phase 2·NCT06647550·160 enrolled
A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
Recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 3·NCT07082114·800 enrolled
The Effect of Alpha Lipoid Acid and Vitamin B Preparation on Diabetic Polyneuropathy in Type 2 Diabetes Mellitus Patient
Recruiting·UUniversiti Sains Malaysia·Phase 2·NCT06568185·76 enrolled
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
Recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT07313813·20 enrolled
A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus
Recruiting·Daewoong Pharmaceutical Co. LTD. logoDaewoong Pharmaceutical Co. LTD.·Phase 3·NCT05466643·240 enrolled
A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients
Recruiting·YYonsei University·Phase 4·NCT06642623·2,862 enrolled
A Study of REGEND003 on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)
Recruiting·RRegend Therapeutics·Phase 1·NCT07275788·15 enrolled
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus
Recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT07299084·40 enrolled
Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus
Recruiting·NNational Center for Global Health and Medicine, Japan·Phase 4·NCT05366868·567 enrolled
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT06982859·95 enrolled
Safety and Efficacy of Human Microbiota Transplantation for Overweight and Obese Type 2 Diabetes Mellitus
Recruiting·ZZhujiang Hospital·Phase 2·NCT05253768·39 enrolled
A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin
Recruiting·GGan & Lee Pharmaceuticals.·Phase 3·NCT07165223·300 enrolled
A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus
Recruiting·AstraZeneca logoAstraZeneca·Phase 1·NCT07433062·28 enrolled
Page 1 of 69

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)